Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 17/20 | 0.59 |
| ▸ | PIM1 | P11309 | 2/20 | 0.57 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CDC7 | O00311 | 1/20 | 0.45 |
| ▸ | PLK4 | O00444 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | IKBKB | O14920 | 1/20 | 0.45 |
| ▸ | RGS12 | O14924 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | GAK | O14976 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.45 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30930832 | 1.00 | PARP1 (0.59) | PARP1PIM1CSNK1DATMNPSR1 | |
| SCHEMBL14336647 | 0.85 | PARP1 (0.56) | PARP1PIM1CSNK1DATMNPSR1 | |
| SCHEMBL14336470 | 0.84 | PARP1 (0.64) | PARP1PIM1CSNK1DLMNATSHR | |
| SCHEMBL14336756 | 0.84 | PARP1 (0.61) | PARP1PIM1CSNK1DATMNPSR1 | |
| SCHEMBL14336667 | 0.84 | PARP1 (0.61) | PARP1PIM1CSNK1DKDM4EAURKA | |
| SCHEMBL14336617 | 0.81 | PARP1 (0.47) | PARP1PIM1CSNK1DATMNPSR1 | |
| SCHEMBL13647432 | 0.81 | PARP1 (0.58) | PARP1PIM1CSNK1DATMNPSR1 | |
| SCHEMBL52171 | 0.81 | PARP1 (0.70) | PARP1PIM1CSNK1D | |
| SCHEMBL13647431 | 0.81 | PARP1 (0.61) | PARP1PIM1CSNK1DGSK3AGSK3B | |
| SCHEMBL61262 | 0.81 | PARP1 (0.74) | PARP1PIM1CSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4469597-A1 | COMPOSITIONS AND METHODS FOR INHIBITING STAG1 EXPRESSION AND USES THEREOF | President And Fellows Of Harvard College (US) | 2024-12-04 | — | — | EP | disclosed |
| EP-4376822-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | Lantern Pharma Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| EP-3612234-B1 | COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE | ADC THERAPEUTICS SA (CH) | 2024-03-13 | — | — | EP | disclosed |
| WO-2024016014-A2 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | LANTERN PHARMA INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2023147400-A1 | COMPOSITIONS AND METHODS FOR INHIBITING STAG1 EXPRESSION AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023010119-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | LANTERN PHARMA INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| US-20220305132-A1 | COMBINATION THERAPY COMPRISING AN ANTI-CD19 ANTIBODY DRUG CONJUGATE AND A PI3K INHIBITOR OR A SECONDARY AGENT | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2022-09-29 | — | — | US | disclosed |
| EP-4028009-A1 | TREATMENT OF HR DEFICIENT CANCER | The Francis Crick Institute Limited (GB) | 2022-07-20 | — | — | EP | disclosed |
| EP-3980079-A1 | COMBINATION THERAPY COMPRISING AN ANTI-CD19 ANTIBODY DRUG CONJUGATE AND A PI3K INHIBITOR OR A SECONDARY AGENT | ADC Therapeutics SA (CH) | 2022-04-13 | — | — | EP | disclosed |
| WO-2022029223-A1 | COMBINATION THERAPY COMPRISING ANTI-KAAG1 ANTIBODY DRUG CONJUGATE AND PARP INHIBITOR | ADC THERAPEUTICS SA (CH) | 2022-02-10 | — | — | WO | disclosed |
| EP-1684736-B1 | DNA DAMAGE REPAIR INHIBITORS FOR TREATMENT OF CANCER | KUDOS PHARM LTD (GB) | 2011-08-24 | — | — | EP | disclosed |
| WO-2011058367-A2 | DIAGNOSTIC TEST FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | WO | disclosed |
| EP-2305221-A1 | Dna damage repair inhibitors for treatment of cancer | Kudos Pharmaceuticals Limited (GB) | 2011-04-06 | — | — | EP | disclosed |
| US-20100249112-A1 | COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS | ASTRAZENECA R&D (SE) | 2010-09-30 | — | — | US | disclosed |
| EP-2167086-A1 | COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS | AstraZeneca AB (SE) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008146035-A1 | COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | WO | disclosed |
| US-20060142231-A1 | DNA damage repair inhibitors for treatment of cancer | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-06-29 | — | — | US | disclosed |
| US-20050227919-A1 | DNA damage repair inhibitors for the treatment of cancer | KUDOS PHARMACEUTICALS LIMITED | 2005-10-13 | — | — | US | disclosed |
| US-6514983-B1 | Inhibitors of the nucleic enzyme poly(adenosine 5'-diphospho-ribose)polymerase | GUILFORD PHARMACEUTICALS INC. | 2003-02-04 | — | — | US | disclosed |
| US-6306889-B1 | FUSED HETEROCYCLIC DRUGS FOR CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2001-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142231-A1 | DNA damage repair inhibitors for treatment of cancer | MRE11, PARP2, ERCC4 | PARP1 4/4885PIM1 3310/4885CSNK1D 3764/4885 |
| US-20220305132-A1 | COMBINATION THERAPY COMPRISING AN ANTI-CD19 ANTIBODY DRUG CONJUGATE AND A PI3K INHIBITOR OR A SECONDARY AGENT | CD22, BTK, CD79B | PARP1 849/4885PIM1 363/4885CSNK1D 3442/4885 |
| US-20100249112-A1 | COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS | CHEK1, CHEK2, PARP1 | PARP1 3/4885PIM1 499/4885CSNK1D 405/4885 |
| US-20050227919-A1 | DNA damage repair inhibitors for the treatment of cancer | MRE11, ERCC4, PARP2 | PARP1 7/4885PIM1 3423/4885CSNK1D 3655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.